
Lurbinectedin Plus Pembrolizumab May Yield Activity in Relapsed SCLC
The combination of lurbinectedin (Zepzelca) and pembrolizumab (Keytruda) demonstrated notable antitumor activity in patients with relapsed small cell lung cancer (SCLC), according to findings from the phase 1/2 LUPER trial (NCT04358237) published in …